Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders: 2019-2025

Historic Net Income towards Common Stockholders for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to -$1.9 million.

  • Eton Pharmaceuticals' Net Income towards Common Stockholders fell 407.34% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 21.91%. This contributed to the annual value of -$3.8 million for FY2024, which is 308.44% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Net Income towards Common Stockholders stood at -$1.9 million, which was up 25.45% from -$2.6 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $5.1 million for Q1 2021, and its period low was -$6.1 million during Q3 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$1.6 million (2025), whereas its average is -$985,727.
  • In the last 5 years, Eton Pharmaceuticals' Net Income towards Common Stockholders surged by 392.62% in 2023 and then tumbled by 407.34% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $1.0 million in 2021, then fell by 12.22% to $912,000 in 2022, then crashed by 347.37% to -$2.3 million in 2023, then spiked by 73.49% to -$598,000 in 2024, then crashed by 407.34% to -$1.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$1.9 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.6 million for Q1 2025.